Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | FABP7 | O15540 | 1/20 | 0.39 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16214739 | 1.00 | SMN1; SMN2 (0.40) | SMN1; SMN2NPC1RAB9ATSHRALDH1A1 | |
| SCHEMBL28922840 | 0.92 | FABP7 (0.44) | SMN1; SMN2NPC1RAB9ATSHRALDH1A1 | |
| SCHEMBL16214742 | 0.89 | SMN1; SMN2 (0.41) | SMN1; SMN2NPC1RAB9ATSHRALDH1A1 | |
| SCHEMBL17365570 | 0.84 | FKBP1A (0.43) | TSHRALDH1A1FABP7FABP5 | |
| SCHEMBL17365553 | 0.84 | FKBP1A (0.43) | TSHRALDH1A1FABP7FABP5 | |
| SCHEMBL16214759 | 0.84 | FKBP1A (0.43) | TSHRALDH1A1FABP7FABP5 | |
| SCHEMBL17365605 | 0.84 | FKBP1A (0.43) | TSHRALDH1A1FABP7FABP5 | |
| SCHEMBL1666476 | 0.83 | SMN1; SMN2 (0.43) | SMN1; SMN2NPC1RAB9ATSHRALDH1A1 | |
| SCHEMBL1668432 | 0.83 | SMN1; SMN2 (0.43) | SMN1; SMN2NPC1RAB9ATSHRALDH1A1 | |
| SCHEMBL1813152 | 0.80 | FABP7 (0.42) | SMN1; SMN2NPC1RAB9ATSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115521325-A | Boronic acid derivatives | 首药控股(北京)股份有限公司 | 2022-12-27 | — | — | CN | disclosed |
| US-9221819-B2 | Spirocyclic compounds as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-29 | — | — | US | disclosed |
| US-8877749-B2 | Spirocyclic compounds as modulators of chemokine receptor activity | Bristol-Myers Squibbs Company (US) | 2014-11-04 | — | — | US | disclosed |
| EP-2486034-A1 | SPIROCYCLIC COMPOUNDS AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2012-08-15 | — | — | EP | disclosed |
| US-20120202802-A1 | SPIROCYCLIC COMPOUNDS AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-09 | — | — | US | disclosed |
| WO-2011061590-A1 | NOVEL CARBOXAMIDE DERIVATIVES AS HIV INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011044197-A1 | SPIROCYCLIC COMPOUNDS AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202802-A1 | SPIROCYCLIC COMPOUNDS AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR1, CXCR1, CCR7 | SMN1; SMN2 4613/4885NPC1 1441/4885RAB9A 942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.